While looking at the Stock's Performance, Esperion Therapeutics, Inc. now shows a Weekly Performance of -23.89%, where Monthly Performance is 13.36%, Quarterly performance is 92.6%, 6 Months performance is 110.59% and yearly performance percentage is 64.6%. Edge Therapeutics, Inc. has a 52-week low of 6.52 and a 52-week high of 13.50. The stock had previously closed at $23.67.
A number of other research firms have also recently commented on ESPR.
05/09/2016 - Edge Therapeutics, Inc. had its "outperform" rating reiterated by analysts at Credit Suisse. Royal Bank of Canada restated a "hold" rating and issued a $15.00 price objective on shares of Esperion Therapeutics in a research report on Tuesday, January 3rd. Zacks Investment Research upgraded shares of Esperion Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, March 2nd.
The 10 analysts offering 12-month price forecasts for Esperion Therapeutics Inc have a median target of 29.50, with a high estimate of 45.00 and a low estimate of 20.00. Stock has got OUTPERFORM rating from 2 analysts of Thomson Reuters, 5 analysts given HOLD rating to the stock and 0 given UNDERPERFORM rating. The price-to-book ratio (P/B Ratio) is a ratio used to compare a stock's market value to its book value.
Meet Julia, a New 'Sesame Street' Muppet with Autism
She's a mother with a son who has autism. "And [they] would have known that he plays in a different way, and that that's okay". Gordon has a son who has high-functioning autism and says it was great for the show to add a character like Julia .
It seems all was forgiven today when Esperion, which has nothing to sell but its own shares, provided a detailed timeline that ends with a new drug application. Advisor Group Inc. now owns 14,437 shares of the biopharmaceutical company's stock valued at $200,000 after buying an additional 85 shares during the last quarter. They now have a United States dollars 33 price target on the stock. Senzar Asset Management LLC bought a new position in shares of Esperion Therapeutics during the fourth quarter worth $4,557,000. (NASDAQ:EDGE) was down -2.13% during the last day of trading, with a day high of 8.83. Dimensional Fund Advisors LP increased its position in Esperion Therapeutics by 54.9% in the fourth quarter. The company's market cap is $14.48 Million, and the average volume is $1.04 Million.
Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Wednesday, February 22nd. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts' consensus estimates of ($0.61) by $0.04. During the same period in the prior year, the company earned ($0.53) EPS.
02/22/2017 - Aegis Capital began new coverage on TG Therapeutics, Inc. giving the company a "buy" rating.
TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. Its lead product candidate is Bempedoic acid, an inhibitor of ATP-citrate lyase that reduces cholesterol biosynthesis that is in Phase III long-term safety and tolerability study.